What is the 13F Pro Quality Score for EDIT?

13F Pro ranks Editas Medicine, Inc. (EDIT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EDIT's current score at https://13fpro.ai/company/EDIT (free sign-up required for the full ranking).

Which hedge funds own the most EDIT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of EDIT include TCG Crossover Management,, BlackRock,, Commodore Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/EDIT as soon as new 13F filings post.

Where does 13F Pro source EDIT data?

All Editas Medicine, Inc. fundamentals and ownership data come directly from SEC EDGAR. Editas Medicine, Inc. files with the SEC under CIK 1650664. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EDIT in?

Editas Medicine, Inc. (EDIT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EDIT research updated on 13F Pro?

EDIT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Editas Medicine, Inc.(EDIT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1650664 EDIT stock profile & AI dashboard →

13F Pro Quality Score

33.4/100

Rank #2,391 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

97.7/100

Profitability

6.3/100

Balance Sheet

7.0/100

Earnings Quality

3.2/100

Free Cash Flow

3.9/100

Institutional Flow

99.3/100

Revenue Scale

8.2/100

Dilution Risk

7.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why EDIT Scores 33/100

exact factor attribution · 2026-09-11

EDIT's composite is driven by revenue growth and institutional flow, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.5 pts

98th pct

Institutional flow

+2.5 pts

99th pct

Earnings growth

+2.3 pts

95th pct

Shareholder dilution

-2.1 pts

7th pct

Capital efficiency

-4.3 pts

7th pct

Earnings quality

-4.7 pts

3th pct

Scale

-6.3 pts

8th pct

Profitability

-6.6 pts

6th pct

Free cash flow

-6.9 pts

4th pct

Latest change (2026-08-05): 11 → 25 · ↑ Revenue growth 27→92

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in EDIT

Events flagged as statistical outliers against EDIT's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-05
EDIT quality score jumped 14 points (11→25) on a new filing
View source filing →

EDIT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Editas Medicine, Inc. (EDIT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EDIT at 33.4/100 on a 32-signal composite quality model, placing it at rank #2,391 of 2,961 stocks — the bottom half of the AI-ranked universe. EDIT scores in the top quartile across institutional flow (99.3), revenue growth (97.7). Areas of concern include earnings quality (3.2) and free cash flow (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Editas Medicine, Inc. reports quarterly revenue of $11.9M, net income of $-18.2M, free cash flow of $-29.7M. Top institutional holders of EDIT by reported 13-F value include TCG Crossover Management, BlackRock, Commodore Capital, based on the most recent SEC filings. EDIT trades on the Nasdaq exchange and files with the SEC under CIK 1650664. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EDIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Editas Medicine, Inc. directly from SEC EDGAR. Editas Medicine, Inc.'s 13F Pro composite quality score has ranged between 3 and 33 since 2021, currently 33.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$11.9M

Net Income

Q2 2026

$-18.2M

Free Cash Flow

Q2 2026

$-29.7M

ROIC

Q2 2026

-46.1%

D/E Ratio

Q2 2026

0.53

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+25.4% YoY

$40.5MFY 2025

FY22 $19.7MFY23 $78.1MFY24 $32.3MFY25 $40.5M

Net Income

+32.5% YoY

$-160.1MFY 2025

FY22 $-220.4MFY23 $-153.2MFY24 $-237.1MFY25 $-160.1M

Operating Income

+36.3% YoY

$-160.0MFY 2025

FY22 $-225.9MFY23 $-169.2MFY24 $-251.2MFY25 $-160.0M

EPS (Diluted)

+37.5% YoY

$-1.80FY 2025

FY22 $-3.21FY23 $-2.02FY24 $-2.88FY25 $-1.80

Total Assets

-45.4% YoY

$186.5MFY 2025

FY22 $514.3MFY23 $499.2MFY24 $341.6MFY25 $186.5M

Total Debt

-6.1% YoY

$58.6MFY 2025

FY22 —FY23 $0.00FY24 $62.4MFY25 $58.6M

Op. Cash Flow

+21.4% YoY

$-165.2MFY 2025

FY22 $-177.3MFY23 $-132.2MFY24 $-210.3MFY25 $-165.2M

Free Cash Flow

+24.3% YoY

$-165.8MFY 2025

FY22 $-181.5MFY23 $-136.9MFY24 $-219.1MFY25 $-165.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$40.5M +25.4%	$32.3M -58.6%	$78.1M +296.3%	$19.7M -22.8%	$25.5M -71.8%	$90.7M
Net Income	$-160.1M +32.5%	$-237.1M -54.7%	$-153.2M +30.5%	$-220.4M -14.5%	$-192.5M -66.0%	$-116.0M
Operating Income	$-160.0M +36.3%	$-251.2M -48.5%	$-169.2M +25.1%	$-225.9M -17.0%	$-193.1M -43.2%	$-134.8M
EPS (Diluted)	$-1.80 +37.5%	$-2.88 -42.6%	$-2.02 +37.1%	$-3.21 -12.6%	$-2.85 -43.9%	$-1.98
Total Assets	$186.5M -45.4%	$341.6M -31.6%	$499.2M -2.9%	$514.3M -24.1%	$677.5M +18.3%	$572.6M
Total Debt	$58.6M -6.1%	$62.4M	$0.00	—	—	—
Operating Cash Flow	$-165.2M +21.4%	$-210.3M -59.1%	$-132.2M +25.5%	$-177.3M -8.3%	$-163.8M +8.9%	$-179.8M
Free Cash Flow	$-165.8M +24.3%	$-219.1M -60.1%	$-136.9M +24.6%	$-181.5M -5.6%	$-171.8M +8.1%	$-187.0M

Get alerted when EDIT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Editas Medicine, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EDIT

TCG Crossover Management, LLC
$36.0M11,111,111 sh
BlackRock, Inc.
$34.3M10,589,990 sh
Commodore Capital LP
$28.8M8,889,000 sh
RA CAPITAL MANAGEMENT, L.P.
$28.8M8,889,000 sh
ADAR1 Capital Management, LLC
$28.8M8,889,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$19.9M6,141,336 sh
Paradigm Biocapital Advisors LP
$18.1M5,586,625 sh
Opaleye Management Inc.
$12.5M3,861,930 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$11.7M3,598,339 sh
Woodline Partners LP
$11.5M3,555,497 sh

Fund	Value	Shares
TCG Crossover Management, LLC	$36.0M	11,111,111
BlackRock, Inc.	$34.3M	10,589,990
Commodore Capital LP	$28.8M	8,889,000
RA CAPITAL MANAGEMENT, L.P.	$28.8M	8,889,000
ADAR1 Capital Management, LLC	$28.8M	8,889,000
VANGUARD CAPITAL MANAGEMENT LLC	$19.9M	6,141,336
Paradigm Biocapital Advisors LP	$18.1M	5,586,625
Opaleye Management Inc.	$12.5M	3,861,930
VANGUARD PORTFOLIO MANAGEMENT LLC	$11.7M	3,598,339
Woodline Partners LP	$11.5M	3,555,497

Companies Similar to EDIT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IPSC

Century Therapeutics, Inc.

AI score

Very similar · 7 shared holders

TCG Crossover Management, LLC RA CAPITAL MANAGEMENT, L.P.Commodore Capital LP

ALT

Altimmune, Inc.

AI score

Similar quality profile · 10 shared holders

TCG Crossover Management, LLC RA CAPITAL MANAGEMENT, L.P.Nantahala Capital Management, LLC

FDMT

4D Molecular Therapeutics, Inc.

AI score

Similar quality profile · 9 shared holders

RA CAPITAL MANAGEMENT, L.P.Opaleye Management Inc.Susquehanna Portfolio Strategies, LLC

ASMB

ASSEMBLY BIOSCIENCES, INC.

AI score

Similar quality profile · 10 shared holders

Commodore Capital LP RA CAPITAL MANAGEMENT, L.P.Paradigm Biocapital Advisors LP

RLAY

Relay Therapeutics, Inc.

AI score

Similar quality profile · 16 shared holders

TCG Crossover Management, LLC Commodore Capital LP ADAR1 Capital Management, LLC

ZLAB

Zai Lab Ltd

AI score

Similar quality profile · 9 shared holders

TCG Crossover Management, LLC ADAR1 Capital Management, LLC RA CAPITAL MANAGEMENT, L.P.

NTLA

Intellia Therapeutics, Inc.

AI score

Similar quality profile · 20 shared holders

RA CAPITAL MANAGEMENT, L.P.Opaleye Management Inc.Susquehanna Portfolio Strategies, LLC

TNGX

Tango Therapeutics, Inc.

AI score

Similar quality profile · 11 shared holders

TCG Crossover Management, LLC Commodore Capital LP Paradigm Biocapital Advisors LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EDIT on your watchlist

Track score changes the day Editas Medicine, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EDIT a good stock to buy?

13F Pro's AI-powered analysis of Editas Medicine, Inc. (EDIT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EDIT are available on the EDIT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EDIT is classified as a small company.

Which hedge funds own EDIT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EDIT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Editas Medicine, Inc.'s investment landscape.